[Istanbul, Türkiye – September 2025] The premium medical aesthetics brand ERBELLA, developed by USCarePharm, recently participated in the international aesthetics symposium “A’dan Z’ye Estetik Zirvesi” held in Türkiye, where it introduced its flagship product ERBELLA AQ to great acclaim from local dermatologists and aesthetic practitioners. The symposium serves as a major academic exchange platform where leading Turkish dermatologists and aesthetic specialists share the latest clinical insights and procedural experiences. Over the years, it has established itself as one of the most influential events in the country’s medical aesthetics community. Highlighting Advanced K-Aesthetic Innovation ERBELLA’s Turkish partner, Dosa Medikal, a leading distributor of medical and aesthetic solutions in Türkiye, played a key role in representing the brand. Through its booth and live demonstrations, Dosa Medikal showcased ERBELLA’s cutting-edge technology and product value to a wide range of local physicians and specialists. At the center of attention was ERBELLA AQ, an innovative liquid-type PLLA skin booster combining poly-L-lactic acid (PLLA) with cross-linked hyaluronic acid (HA) in a ready-to-use suspension form. Unlike conventional powder-type PLLA products, ERBELLA AQ requires no reconstitution, ensuring higher procedural convenience and stability. Next-Generation Formulation for Natural Volume and Safety This liquid formulation technology enhances clinical usability for practitioners while minimizing the risk of nodule formation. The product provides an instant, natural-looking volumizing effect post-procedure, while the PLLA component gradually stimulates collagen synthesis for long-lasting improvement. Meanwhile, the cross-linked HA component ensures sustained hydration and structural support. Thanks to its stable suspension format, ERBELLA AQ significantly reduces the risk of granuloma or nodule formation, offering a distinct safety advantage over conventional fillers. At the symposium, local doctors praised its “immediate volume enhancement and natural longevity”, which drew strong attention throughout the event. Expanding Presence in Türkiye and Beyond By participating in the symposium, ERBELLA has strengthened its brand recognition in the Turkish market and accelerated its expansion through strategic local partnerships. The brand aims to further establish itself globally as a next-generation aesthetic solution that achieves natural and lasting beauty through scientifically advanced bio-formulations. “ERBELLA AQ is not just a volumizing product — it’s a solution that delivers natural, enduring beauty,” said an ERBELLA representative. “This symposium was a meaningful opportunity to directly communicate its value to local experts in the aesthetic field.” With Türkiye’s growing status as a global hub for beauty and aesthetics, driven by its strategic position between Europe and the Middle East and its strong beauty culture, the future market potential for ERBELLA AQ looks exceptionally promising.

2025.10.13

ERBELLA, the premium medical aesthetics brand by USCarePharm, announced its successful participation in the 15th Annual Summer Conference of the Korean Academy of Aesthetic and Anti-Aging Dermatology (KAAD), held on August 10 at Seoul Dragon City Hotel. KAAD is a highly respected academic society comprised of board-certified dermatologists in Korea, setting authoritative guidelines for anti-aging treatments including botulinum toxin and filler procedures. This year’s summer conference featured a comprehensive program covering basic science, advanced techniques, clinical applications, and emerging practices, designed to enhance the expertise of participating physicians. Showcasing ERBELLA’s Skin Booster Line At the event, ERBELLA unveiled its innovative liquid PLLA skin booster, ERBELLA PLA Plus AQ, alongside a lineup of boosters tailored to diverse skin concerns. The booth drew strong interest with engaging activities such as product preference surveys, brand quizzes, and prize events, further amplifying audience engagement. Over 200 dermatologists participated in the product survey, demonstrating significant interest in ERBELLA’s portfolio. Among the highlights were: ERBELLA NMN – improves skin texture with NMN-based anti-aging benefits Melathion – a brightening solution for pigmentation care Anti-AC PTT – acne solution leveraging patented Theramogen AT for anti-inflammatory efficacy ExoRN – a regenerative booster combining exosomes and PDRN Spotlight on ERBELLA PLA Plus AQ The most inquired-about product of the day was ERBELLA PLA Plus AQ, the world’s first commercialized liquid PLLA skin booster. Developed using USCarePharm’s patented technology, this product eliminates the need for a separate reconstitution process and features uniformly porous PLLA particles. These properties enhance cell adhesion, improve skin texture, and provide lasting hydration, positioning ERBELLA PLA Plus AQ as a breakthrough in skin rejuvenation. Advancing K-Anti-Aging Solutions “Through this conference, we were able to share the latest developments in anti-aging research with Korean dermatologists and exchange valuable clinical insights,” said an ERBELLA representative. “Moving forward, ERBELLA will continue to provide trusted K-Anti-Aging solutions and pioneer a new paradigm in aesthetic medicine.” Expanding Global Footprint Following the KAAD conference, ERBELLA is set to participate in InterCHARM Russia and Beautyworld Middle East (Dubai) this October. With continuous product innovation and global marketing initiatives, the brand aims to strengthen its position as a leading player in the international medical aesthetics market.

2025.08.22 16:20

USCarePharm Co., Ltd., a leader in natural material-based R&D, announced its recent presentation of new research on vascular health functional ingredients at the Annual Conference of the Korean Society of Pharmacognosy. During the academic forum, USCarePharm unveiled the results of its advanced research into plant-derived bioactive compounds that demonstrated efficacy in supporting vascular wall integrity and circulatory health. The study focused on a newly identified material, USCP0112, which showed promise in improving endothelial function, reducing oxidative stress, and modulating lipid metabolism — all crucial factors in vascular wellness. This achievement is part of USCarePharm’s broader UMAP Tech™ platform, which specializes in the systematic discovery, screening, and optimization of high-performance natural ingredients for use in pharmaceuticals, functional foods, and cosmeceuticals. “The results we shared reflect years of targeted research in functional ingredients derived from traditional medicinal plants,” said CEO Song Seok-jin. “We are committed to transforming these findings into clinically meaningful applications that promote cardiovascular wellness and overall health.” The presentation further strengthens USCarePharm’s reputation as a pioneer in bio-convergent healthcare innovation, capable of bridging the gap between traditional natural remedies and scientifically validated modern therapeutics. USCarePharm plans to continue collaboration with academic institutions and industry partners to accelerate the commercialization of science-based natural health solutions.

2025.07.28 14:10